CALCIUM CATION

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	Ca
Molecular Weight	40.078
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	2

SHOW SMILES / InChI

Structure Search

SMILES

[Ca++]

InChI

InChIKey=BHPQYMZQTOCNFJ-UHFFFAOYSA-N

InChI=1S/Ca/q+2

HIDE SMILES / InChI

Description
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details

Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Hypocalcemia 75 Sources: http://www.globalrph.com/calcium_supplements.htm	Primary	Not Provided 504	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 174 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26265479	Palliative	Phase I 428	Unknown Approved Use Unknown
Cystic fibrosis 120 Sources: https://clinicaltrials.gov/ct2/show/NCT01543191	Palliative	Phase I 428	Unknown Approved Use Unknown
Unknown 2578
Hypocalcemia 75 Sources: https://www.drugs.com/mmx/calcium-phosphate-dibasic.html	Primary	Approved 8429	Unknown Approved Use Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred

PubMed

Title	Date	PubMed
Transient kinetic analysis of the 130-kDa myosin I (MYR-1 gene product) from rat liver. A myosin I designed for maintenance of tension?	1999 Jul 30	10419463
Aluminum is a weak agonist for the calcium-sensing receptor.	1999 May	10231437
Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein.	1999 Nov	10535458
Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells.	2000 Aug	10970766
A family of gamma-like calcium channel subunits.	2000 Mar 24	10734232
Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway.	2000 May	10780946
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells.	2000 Nov	11040061
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.	2000 Nov 10	11073891
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds.	2001 Dec 21	11592964
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.	2001 Feb 16	11179201
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.	2001 Feb 9	11071898
Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D.	2001 Jun	11356622
[Acute renal failure caused by hypercalcemia].	2001 Jun 10	11464680
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.	2001 Jun 8	11382382
Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines.	2001 Mar	11181528
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes.	2001 Mar 2	11230109
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.	2001 Oct	11606325
Familial intrahepatic cholestasis 1: studies of localization and function.	2001 Oct	11584374
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.	2001 Sep	11527950
A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein.	2001 Sep 15	11535132
Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze.	2001 Sep 7	11553362
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats.	2002	12421626
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells.	2002 Dec	12456425
Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.	2002 Feb	11796525
Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice.	2002 Mar 15	11897840
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons.	2002 Nov 4	12445469
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit.	2002 Sep	12181424
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death.	2002 Sep 6	12383957
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension.	2003 Jan	12388232
Lactose behaviour in the presence of lactic acid and calcium.	2016 Aug	27600977

Patents

Sample Use Guides

In Vivo Use Guide

oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid). inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

CALCIUM CATION

Common Name

English

CALCIUM(2+)

Systematic Name

English

CA2+

Common Name

English

CALCIUM (II) ION

Common Name

English

CALCIUM(2+) ION

Common Name

English

CALCIUM ION(2+)

Common Name

English

CALCIUM, ION(CA2+)

Common Name

English

CALCIUM ION

Common Name

English

Classification Tree Code System Code

LOINC

13959-2